TB-500
TB-500, also written TB 500, is supplied by White Label Peptides as a lyophilised powder in multi-dose vials, for laboratory and research use, to business buyers only. It sits in our recovery and repair category. Every batch is verified by HPLC and ships with its own Certificate of Analysis.
| Compound | TB-500 |
|---|---|
| Full name | Thymosin Beta-4 Fragment |
| Classification | Thymosin Beta-4 Analogue |
| Peptide type | Synthetic Peptide Fragment |
| Molecular formula | C212H350N56O78S |
| Molecular weight | Approximately 4963 g/mol |
| Structure | TB-500 is a synthetic peptide version of the active region of Thymosin Beta-4, a naturally occurring peptide involved in cellular migration and tissue-related research processes. |
| Form | Lyophilised powder (vials) or ready-to-use solution (pre-filled pens) |
| Appearance | White to off-white lyophilised powder prior to reconstitution |
| Presentation | Vials: 2 mg, 5 mg, 10 mg. Pre-filled pens: 10 mg |
| Reconstitution | Typically reconstituted using: Bacteriostatic water - Sterile laboratory-grade water |
| Storage | Store refrigerated at 2-8°C in a cool, dry environment away from direct sunlight. Long-term storage may require freezing conditions prior to reconstitution. |
| Also written | TB 500, TB 500 peptide |
Specification data is provided for identification and procurement. It is not dosing guidance and it is not a claim of any effect.
Evidence and status
- Lab work
- Animal studies
- Human studies
- Approved label
Reviewed 2026-08-26. Regulatory status is stated for procurement and varies by market. It is not legal advice.
Research
What the published literature examined
Research has examined TB-500 primarily as an analytical and doping-control problem rather than as a therapeutic candidate. A 2012 study characterised the synthesis and mass-spectrometric signature of the acetylated thymosin beta-4 17-23 fragment isolated from a commercial product. A 2012 equine doping-control study administered the compound subcutaneously to thoroughbred geldings and measured plasma and urine concentrations of the parent peptide and its metabolites. A 2024 study quantified it in rats and in in-vitro systems including human serum and liver fractions, and tested it in a scratch-wound fibroblast assay where closure did not differ significantly from vehicle.
What is not established
There is no human data of any kind. An FDA search of PubMed, Embase, ClinicalTrials.gov, DailyMed, Drugs@FDA and FAERS in 2026 found no clinical study, no case report, and no record of the compound being administered to a human being.
What distinguishes TB-500
TB-500 and thymosin beta-4 are not the same substance, and most published thymosin beta-4 research does not concern TB-500. TB-500 is the acetylated 17-23 heptapeptide Ac-LKKTETQ; thymosin beta-4 is the full 43-residue protein. Acetylation alters charge, hydrophobicity and binding, so the parent protein's pharmacology does not transfer. Its documented in-vivo history also begins in racehorses rather than a clinic: the only published pharmacokinetic study in a live animal is a Jockey Club doping-control study.
Sources
- US FDA. Briefing document, Pharmacy Compounding Advisory Committee: evaluation of TB-500-related bulk drug substances, 15 May 2026
- Ho ENM et al. Doping control analysis of TB-500 in equine urine and plasma. J Chromatogr A. 2012;1265:57-69
- Esposito S et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500. Drug Test Anal. 2012;4(9):733-8
- Rahaman KA et al. Simultaneous quantification of TB-500 and its metabolites in vitro and in rats. J Chromatogr B. 2024;1235:124033
- World Anti-Doping Agency. 2026 Prohibited List, section S2.3
This page describes a compound as a material and summarises published research about it. It is for general and procurement information only. It is not medical advice, not a treatment recommendation, and not guidance on use. Supplied for laboratory and research use, not for human consumption.
Specification
About this compound
The specification below is the batch-independent data. Purity and analysis date vary by batch, so they appear on the certificate issued with your order rather than on this page.
What this compound is
TB-500 in supply terms
TB-500 carries molecular formula C212H350N56O78S and a molecular weight of approximately 4963 g/mol, one of the heavier fragment-class peptides in the recovery grouping. It is synthesized to correspond to the active region of Thymosin Beta-4, a naturally occurring protein, which places it in the catalogue as a Thymosin Beta-4 analogue rather than the full-length native protein. That distinction is structural: TB-500 represents a defined active-region fragment, not the complete parent sequence. Supplied as a lyophilised powder in multi-dose research vials for injectable research format, it presents white to off-white before reconstitution. Standard fill is 10mg per vial, typically reconstituted with bacteriostatic water or sterile laboratory-grade water. Storage follows the standard cold-chain band across this recovery-category range: refrigerated at 2-8C, protected from direct sunlight, with freezing recommended if the vial will be held for an extended period before reconstitution. TB-500 is also the heavier of the two components in the BPC-157 and TB-500 combination product listed separately in this catalogue, worth noting when cross-checking total peptide content and pricing between the standalone vial and the blended presentation.
This section describes the compound as a material. It makes no claim about any effect and is not guidance on use.
What varies by batch
The page identifies the compound. The certificate records the batch.
Purity, method, analysis date and issuing party belong on the batch record rather than in page copy.
| Send the volume you need for TB-500 and your delivery country. We will quote against it. | Request pricing |
Same category
Also in Recovery and Repair
| Compound | Identifier | Presentation |
|---|---|---|
| BPC-157 | C62H98N16O22 | Vials: 5 mg, 10 mg. Pre-filled ... |
| BPC-157 + TB-500 (Wolverine Stack) | On request | Vials: 5+5 mg, 10+10 mg. Pre-fi... |
| KPV | 67727-97-3 | Pre-filled pens: 10 mg |
| LL-37 | 597562-32-8 | Vials: 10 mg. Pre-filled pens: ... |
Questions
Supply, answered
Is TB-500 available for private label?
Yes. It can be supplied under your own brand on the vial and the carton, with the Certificate of Analysis issued under your product name.
What is the minimum order quantity?
Set for this compound specifically and confirmed at the enquiry stage, before you commit.
What purity is supplied?
98 percent or higher, verified by HPLC. The certificate issued with your batch carries the actual figure for that batch.
How is it shipped?
As lyophilised powder in multi-dose vials, packed for transit. Delivery in 5 to 7 days once the batch is released.
We already buy TB-500. Can you quote against our current volume?
Yes. Send the volume and the delivery country. Pricing is tiered per compound, so the quote reflects what you buy rather than a list price.
Can you supply TB-500 as a second source?
Yes. Terms are agreed per compound, so you can add TB-500 without moving anything else you buy elsewhere.
Request pricing for TB-500
Indicative volume and delivery country is enough to start. We reply within one working day.